Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective.
J Thromb Thrombolysis
; 53(2): 273-281, 2022 Feb.
Article
in English
| MEDLINE | ID: covidwho-1401065
ABSTRACT
SARS-CoV-2 represents the causative agent of the current pandemic (COVID-19). The drug repurposing technique is used to search for possible drugs that can bind to SARS-CoV-2 proteins and inhibit viral replication. In this study, the FDA-approved antiplatelets are tested against the main protease and spike proteins of SARS-CoV-2 using in silico methods. Molecular docking and molecular dynamics simulation are used in the current study. The results suggest the effectiveness of vorapaxar, ticagrelor, cilostazol, cangrelor, and prasugrel in binding the main protease (Mpro) of SARS-CoV-2. At the same time, vorapaxar, ticagrelor, and cilostazol are the best binders of the spike protein. Therefore, these compounds could be successful candidates against COVID-19 that need to be tested experimentally.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Platelet Aggregation Inhibitors
/
SARS-CoV-2
Limits:
Humans
Language:
English
Journal:
J Thromb Thrombolysis
Journal subject:
Vascular Diseases
Year:
2022
Document Type:
Article
Affiliation country:
S11239-021-02558-5
Similar
MEDLINE
...
LILACS
LIS